An International Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma

Trial Profile

An International Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Melphalan (Primary)
  • Indications Cholangiocarcinoma; Liver cancer
  • Focus Therapeutic Use
  • Sponsors Delcath Systems
  • Most Recent Events

    • 25 Jul 2017 Planned End Date changed from 1 Aug 2016 to 1 Feb 2018.
    • 25 Jul 2017 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2017.
    • 18 Oct 2016 According to a Delcath Systems media release, the 11-patient cohort of ICC patients is near completion and top-line results are expected by the end of he year 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top